Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

微泰医疗
MICROTECH MEDICAL

MicroTech Medical (Hangzhou) Co., Ltd.
微泰醫療器械（杭州）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2235)

POSITIVE PROFIT ALERT

This announcement is made by MicroTech Medical (Hangzhou) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**", and each a "**Director**") of the Company hereby informs the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary review on the unaudited consolidated management accounts of the Group for the year ended December 31, 2025 (the "**Reporting Period**") pursuant to the Accounting Standards for Business Enterprises promulgated by the Ministry of Finance of the PRC and relevant requirements, the estimated results are as follows:

1) It is estimated that the income of the Group during the Reporting Period will amount to not less than RMB650.0 million, representing a year-on-year increase of approximately 88.1% as compared to RMB345.6 million for the year ended December 31, 2024.

2) It is estimated that the Group will realize a net profit attributable to owners of the parent company of not less than RMB38.0 million during the Reporting Period, representing an increase of RMB101.1 million as compared to RMB-63.1 million for the year ended December 31, 2024.

The Group realized a significant income growth during the Reporting Period and a turnaround from loss to profit, mainly attributable to:

1) the income from continuous glucose monitoring system (CGMS), one of the Group's pivotal products, demonstrated continuous strong growth;

2) the result of overseas market expansion was outstanding, the LinX continuous glucose monitoring system was successfully launched in various countries, international income achieved significant year-on-year increase; and

3) continuous deepening of lean management and significant boost of operation efficiency, the proportion of selling expenses and administrative expenses to income realized a significant decrease.

As the unaudited consolidated financial results of the Group for the Reporting Period have not yet been finalized, information contained in this announcement is based on information currently available to the Board and the preliminary unaudited consolidated management accounts of the Group for the Reporting Period, such information has not yet been reviewed by auditor of the Company or the audit committee. The actual financial results of the Group for the Reporting Period are subject to adjustment and may differ from information contained in this announcement. Such results are expected to be published by the end of March 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
MicroTech Medical (Hangzhou) Co., Ltd.
Zheng Pan
Chairman of the Board

Hangzhou, the PRC, February 26, 2026

As at the date of this announcement, the executive Directors are Dr. Zheng Pan, Dr. Yu Fei, Dr. Shi Yonghui and Ms. Liu Xiu; the non-executive Directors are Mr. Mao Shuo and Ms. Gao Yun; and the independent non-executive Directors are Dr. Li Lihua, Ms. Wang Chunfeng, Mr. Ho Kin Cheong Kelvin and Dr. Cheng Hua.